West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Currency in USD	2025
Operating Income	584.90 Million
Income Before Tax	600.90 Million
Income Tax Expense	121.60 Million
Net Income	493.70 Million
Eps	6.83
Epsdiluted	6.79
Weighted Average Shs Out	72.30 Million
Weighted Average Shs Out Dil	72.70 Million
Research And Development Expenses	74.30 Million
Selling General And Administrative Expenses	393.60 Million
Depreciation And Amortization	171.40 Million
Interest Expense	500.00 Thousand
Interest Income	17.50 Million
Net Interest Income	17.00 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	1.10 Billion
Ebitda	756.30 Million
Source	edgar

West Pharmaceutical Services, Inc. Annual Reports (10-K)